Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05679232

Hydrogel Coating to Reduce Post-surgical Infection After Joint Arthroplasty

Randomized, Controlled, Monocentric, Feasibility Clinical Investigation to Assess the Safety and Preliminary Clinical Performance of a Hydrogel Coating to Reduce Post-surgical Infection After Joint Arthroplasty

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
56 (estimated)
Sponsor
Medacta International SA · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The goal of this randomized, controlled, monocentric, single-blind, 2-arm, feasibility clinical investigation is to evaluate the safety of MectaShield hydrogel coating and to capture its preliminary clinical performance in the prevention of early peri-prosthetic joint infection (PJI) in patients undergoing cementless revision hip arthroplasty. The main questions it aims to answer are: * demonstrate that the hydrogel coating MectaShield does not interfere with primary stability; * evaluate clinical and functional outcomes, the rate of PJI and possible adverse events. Participants will undergo cementless revision hip arthroplasty; during surgery MectaShield hydrogel coating is applied on orthopaedic implants' surfaces (femoral stem and, if revised, acetabular cup) as a protective barrier for the prevention of bacterial adhesion. Surgery and follow-up are completed as per local standard practice. Stability will be assessed radiologically, while functional outcomes and PJI will be monitored by HOOS-PS, ASESPIS scores and according to the consensus document presented by European Society of Radiology (ESRa), the European Association of Nuclear Medicine (EANM), the European Bone and Joint Infection Society (EBJIS), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Researchers will compare the results of the treatment group with those from a control group receiving cementless revision hip arthroplasty without the application of MectaShiled hydrogel coating.

Detailed description

Peri-prosthetic joint infection (PJI) is among the first three reasons for joint replacement failure. PJI is a serious condition that may lead to repeated surgical interventions, prolonged hospitalization, high costs, and significant morbidity, although low mortality. To address this concern, antibacterial coating of implants has been proposed, as the adherence of the microorganisms to the implant, forming a biofilm, plays a strategic role in the pathogenesis of PJI. MectaShield (Medacta International SA) is a novel resorbable hydrogel coating intended to be spread on orthopaedic implants' surfaces as a protective barrier for the prevention of PJI. The study aims to evaluate the safety of MectaShield and to capture its preliminary clinical performance in the prevention of early PJI in patients undergoing cementless revision hip arthroplasty. Patients suitable to receive MectaShield for cementless revision hip arthroplasty will be invited to take part to the study during the preoperative visit. Follow-up is performed after 3 and 12 months. Data collection includes clinical and functional data for preoperative and postoperative assessments, as well as intraoperative details, adverse events and device deficiencies. Patients will be randomized 1:1 in 2 groups: * Control (no MectaShield) * MectaShield hydrogel coating (+ antibiotic) The primary objective is to demonstrate that MectaShield hydrogel coating does not interfere with early primary stability at 3 months of follow-up Secondary objectives are: 1. To demonstrate that MectaShield does not interfere with primary stability at 12 months of follow-up 2. To evaluate clinical and functional outcomes at 3 and 12 months of follow-up 3. To evaluate the rate of PJI at 3 and 12 months of follow-up 4. To evaluate the occurrence of adverse events and device deficiencies

Conditions

Interventions

TypeNameDescription
DEVICEHydrogel coatinghydrogel coating applied to implant's surfaces during cementless hip revision arthroplasty
PROCEDUREControlstandard cementless hip revision arthroplasty

Timeline

Start date
2022-12-06
Primary completion
2027-03-06
Completion
2027-12-06
First posted
2023-01-10
Last updated
2025-05-11

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT05679232. Inclusion in this directory is not an endorsement.